GoPubMed Proteins lists recent and important papers and reviews for
proteins. Page last changed on 19 Dec 2016.
NOP16 nucleolar protein homolog
HSPC111, HBV pre-S2 trans-regulated protein 3
NOP16 is transcriptionally regulated by c-Myc (MYC; MIM 190080), upregulated in breast cancer, and overexpression is associated with poor patient survival (Butt et al., 2008).[supplied by OMIM, Jun 2009] (from
NCBI)
Sponsored links
Top mentioned proteins:
c-Myc, Rhodopsin, PC1, CtBP2, RhoA
Papers on
HSPC111
ROCK has a crucial role in regulating prostate tumor growth through interaction with c-Myc.
Beijing, China. In Oncogene, 2015
ROCK could increase the transcriptional activity of c-Myc by promoting c-Myc protein stability, and ROCK inhibition reduced c-Myc-mediated expression of mRNA targets (such as HSPC111) and microRNA targets (such as miR-17-92 cluster).
CtBP2 could promote prostate cancer cell proliferation through c-Myc signaling.
Tianjin, China. In Gene, 2014
Additionally, CtBP2 inhibition could decrease the level of c-Myc and its direct transcriptional target, HSPC111.
HSPC111 governs breast cancer growth by regulating ribosomal biogenesis.
Tianjin, China. In Mol Cancer Res, 2014
In this report, a crucial role for the HSPC111 (NOP16) multiprotein complex in governing ribosomal biogenesis and tumor growth was determined.
Quantum dots (QDs) restrain human cervical carcinoma HeLa cell proliferation through inhibition of the ROCK-c-Myc signaling.
Taiyuan, China. In Integr Biol (camb), 2013
HSPC111).
Molecular characterizations of Nop16 in murine mammary tumors with varying levels of c-Myc.
Duluth, United States. In Transgenic Res, 2012
NOP16, also known as HSPC111, has been identified as a MYC and estrogen regulated gene in in vitro studies, hence coexpression levels were strongly correlated.
The estrogen and c-Myc target gene HSPC111 is over-expressed in breast cancer and associated with poor patient outcome.
GeneRIF
Australia. In Breast Cancer Res, 2007
HSPC111 is an estrogen and c-Myc target gene that is over-expressed in breast cancer and is associated with an adverse patient outcome.
